{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/XNCR/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-17T04:33:58.377Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":6318,"canonical_name":"Xencor Inc","cik":"0001326732","uei":null,"lei":null,"duns":null,"ticker":"XNCR"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":37,"clinical":4},"count":41,"timeline":[{"ts":"2026-08-05","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Xencor Inc — 2026-08-05","url_slug":"/sec/cik-0001326732/10-q/0001326732-26-000056","accession_number":"0001326732-26-000056","importance":45},{"ts":"2026-08-05","kind":"sec.filing","form_type":"8-K","title":"8-K — Xencor Inc — 2026-08-05","url_slug":"/sec/cik-0001326732/8-k/0001326732-26-000055","accession_number":"0001326732-26-000055","importance":35},{"ts":"2026-08-03","kind":"clinical.trial","reporter":"Xencor, Inc.","title":"Study of XmAb412 in Healthy Participants","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07713485","excerpt":"[\"Not Applicable - Healthy Adult Participants\"]","importance":30},{"ts":"2026-07-31","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Xencor Inc — 2026-07-31","url_slug":"/sec/cik-0001326732/schedule-13g/0002100119-26-001489","accession_number":"0002100119-26-001489","importance":55},{"ts":"2026-07-29","kind":"sec.filing","form_type":"8-K","title":"8-K — Xencor Inc — 2026-07-29","url_slug":"/sec/cik-0001326732/8-k/0001326732-26-000049","accession_number":"0001326732-26-000049","importance":35},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Xencor Inc — 2026-07-08","url_slug":"/sec/cik-0001326732/4/0001313936-26-000004","accession_number":"0001313936-26-000004","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Xencor Inc — 2026-07-08","url_slug":"/sec/cik-0001326732/4/0001462354-26-000006","accession_number":"0001462354-26-000006","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Xencor Inc — 2026-07-08","url_slug":"/sec/cik-0001326732/4/0001647647-26-000002","accession_number":"0001647647-26-000002","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Xencor Inc — 2026-07-08","url_slug":"/sec/cik-0001326732/4/0001758108-26-000004","accession_number":"0001758108-26-000004","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Xencor Inc — 2026-07-08","url_slug":"/sec/cik-0001326732/4/0002079360-26-000002","accession_number":"0002079360-26-000002","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — Xencor Inc — 2026-06-22","url_slug":"/sec/cik-0001326732/4/0001758108-26-000002","accession_number":"0001758108-26-000002","importance":30},{"ts":"2026-06-18","kind":"sec.form144","reporter":"Feigal Ellen","title":"Director","shares":6843,"usd_value":89370,"security_title":"Common","approx_sale_date":"2026-06-18","accession_number":"0001959173-26-004758","importance":40.017873916},{"ts":"2026-06-18","kind":"sec.insider.s","reporter":"Feigal Ellen","title":null,"shares":6843,"price_per_share":13.06,"usd_value":89370,"security_title":"Common Stock","importance":35.08936958},{"ts":"2026-06-18","kind":"sec.filing","form_type":"8-K","title":"8-K — Xencor Inc — 2026-06-18","url_slug":"/sec/cik-0001326732/8-k/0001326732-26-000045","accession_number":"0001326732-26-000045","importance":35},{"ts":"2026-06-18","kind":"sec.filing","form_type":"144","title":"144 — Xencor Inc — 2026-06-18","url_slug":"/sec/cik-0001326732/144/0001959173-26-004758","accession_number":"0001959173-26-004758","importance":30},{"ts":"2026-06-17","kind":"sec.filing","form_type":"4","title":"4 — Xencor Inc — 2026-06-17","url_slug":"/sec/cik-0001326732/4/0001462354-26-000004","accession_number":"0001462354-26-000004","importance":30},{"ts":"2026-06-16","kind":"sec.insider.a","reporter":"GORMAN KEVIN CHARLES","title":null,"shares":10302,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-16","kind":"sec.insider.a","reporter":"SIMPSON TODD E","title":null,"shares":10302,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-16","kind":"sec.insider.a","reporter":"RANIERI RICHARD J","title":null,"shares":10302,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-16","kind":"sec.insider.a","reporter":"Montgomery Alan Bruce","title":null,"shares":10302,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-16","kind":"sec.insider.a","reporter":"GUSTAFSON KURT A","title":null,"shares":10302,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-16","kind":"sec.insider.a","reporter":"Klencke Barbara","title":null,"shares":10302,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-16","kind":"sec.insider.a","reporter":"Feigal Ellen","title":null,"shares":10302,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-16","kind":"sec.insider.a","reporter":"Deshaies Raymond Joseph","title":null,"shares":10302,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-15","kind":"sec.form144","reporter":"GORMAN KEVIN CHARLES","title":"Director","shares":7527,"usd_value":92657,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001959173-26-004624","importance":40.018531474},{"ts":"2026-06-15","kind":"sec.form144","reporter":"RANIERI RICHARD J","title":"Director","shares":5474,"usd_value":67385,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001959173-26-004634","importance":40.013476988},{"ts":"2026-06-15","kind":"sec.form144","reporter":"GUSTAFSON KURT A","title":"Director","shares":5474,"usd_value":67385,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001959173-26-004632","importance":40.013476988},{"ts":"2026-06-15","kind":"sec.form144","reporter":"Montgomery Alan Bruce","title":"Director","shares":5064,"usd_value":62338,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001959173-26-004639","importance":40.012467568},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"GORMAN KEVIN CHARLES","title":null,"shares":7527,"price_per_share":12.31,"usd_value":92657,"security_title":"Common Stock","importance":35.09265737},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"RANIERI RICHARD J","title":null,"shares":5474,"price_per_share":12.31,"usd_value":67385,"security_title":"Common Stock","importance":35.06738494},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"GUSTAFSON KURT A","title":null,"shares":5474,"price_per_share":12.31,"usd_value":67385,"security_title":"Common Stock","importance":35.06738494},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Montgomery Alan Bruce","title":null,"shares":5064,"price_per_share":12.31,"usd_value":62338,"security_title":"Common Stock","importance":35.06233784},{"ts":"2026-06-15","kind":"sec.filing","form_type":"144","title":"144 — Xencor Inc — 2026-06-15","url_slug":"/sec/cik-0001326732/144/0001959173-26-004632","accession_number":"0001959173-26-004632","importance":30},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"Xencor, Inc.","title":"Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07593092","excerpt":"[\"Ovarian Cancer\"]","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Xencor Inc — 2026-05-15","url_slug":"/sec/cik-0001326732/schedule-13g-a/0000935836-26-000264","accession_number":"0000935836-26-000264","importance":30},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"Xencor, Inc.","title":"A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07284797","excerpt":"[\"Healthy\",\"Idiopathic Inflammatory Myopathies\",\"Systemic Sclerosis\",\"Sj\\u00f6gren's Disease\"]","importance":30},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Xencor, Inc.","title":"XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer","security_title":"PHASE2","status":"COMPLETED","accession_number":"NCT05005728","excerpt":"[\"Metastatic Castration-Resistant Prostate Cancer\"]","importance":45},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Xencor Inc — 2026-04-27","url_slug":"/sec/cik-0001326732/def-14a/0001326732-26-000031","accession_number":"0001326732-26-000031","importance":40},{"ts":"2026-04-27","kind":"sec.filing","form_type":"8-K","title":"8-K — Xencor Inc — 2026-04-27","url_slug":"/sec/cik-0001326732/8-k/0001326732-26-000030","accession_number":"0001326732-26-000030","importance":35},{"ts":"2026-04-27","kind":"sec.filing","form_type":"ARS","title":"ARS — Xencor Inc — 2026-04-27","url_slug":"/sec/cik-0001326732/ars/0001326732-26-000033","accession_number":"0001326732-26-000033","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Xencor Inc — 2026-04-27","url_slug":"/sec/cik-0001326732/defa14a/0001326732-26-000032","accession_number":"0001326732-26-000032","importance":30}]}